Surgical Pathologist
Quest Diagnostics Incorporated | |
United States, Washington, Seattle | |
Nov 04, 2026 | |
|
Job Description
Compensation range - $400,000 - $425,000 annually PhenoPath, a Quest Diagnostics Company, is a national reference laboratory in Seattle, WA committed to rendering "diagnoses you can count on" for cases ranging from the most complex to the most straightforward. Position Description PhenoPath is recruiting a full-time Surgical Pathologist to provide signout coverage at three sites in the Seattle area: PhenoPath laboratories and two out patient clinic based pathology practice sites with one located in Seattle, WA and the other located in Everett, WA. The successful candidate will participate in general surgical pathology signout with an emphasis on GI, breast, and GU tissue diagnoses as well as peripheral blood smears, frozen sections, and Crystal ID studies at the two outpatient sites. At the PhenoPath location, signout will include immunohistochemical cases, primary pathology, FISH, and consults). Candidates should bring general surgical pathology sign out experience and one or moreareas of subspecialty expertise/interest in anatomic pathology. Responsibilities: Key position requirements include:
Qualifications:
To Apply Please register and complete the online application atcareers.questdiagnostics.com, clicking "Job Search" and following the prompts. Quest Diagnostics will only contact qualified candidates for interviews. Quest Diagnostics is an equal opportunity employer. Specific Inquiries can be directed to: asysha.x.hogan@questdiagnostics.com 72820 Quest Diagnostics honors our service members and encourages veterans to apply. While we appreciate and value our staffing partners, we do not accept unsolicited resumes from agencies. Quest will not be responsible for paying agency fees for any individual as to whom an agency has sent an unsolicited resume. Equal Opportunity Employer: Race/Color/Sex/Sexual Orientation/Gender Identity/Religion/National Origin/Disability/Vets or any other legally protected status. | |
Nov 04, 2026